1	4	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	believed	_	_	VBN	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	ideal	_	_	JJ	_	_	_	_	_
7	vaccine	_	_	NN	_	_	_	_	_
8	against	_	_	IN	_	_	_	_	_
9	Leishmania	_	_	NNP	_	_	_	_	_
10	spp	_	_	NN	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	should	_	_	MD	_	_	_	_	_
2	have	_	_	VB	_	_	_	_	_
3	epitopes	_	_	NNS	_	_	_	_	_
4	that	_	_	WDT	_	_	_	_	_
5	will	_	_	MD	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	recognized	_	_	VBN	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	APCs	_	_	NNPS	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	will	_	_	MD	_	_	_	_	_
12	be	_	_	VB	_	_	_	_	_
13	able	_	_	JJ	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	trigger	_	_	VB	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	T-	_	_	NN	_	_	_	_	_
18	lymphocyte	_	_	NN	_	_	_	_	_
19	effector	_	_	NN	_	_	_	_	_
20	response	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	maintain	_	_	VB	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	long-lasting	_	_	JJ	_	_	_	_	_
25	immune	_	_	JJ	_	_	_	_	_
26	memory	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	which	_	_	WDT	_	_	_	_	_
29	would	_	_	MD	_	_	_	_	_
30	be	_	_	VB	_	_	_	_	_
31	critical	_	_	JJ	_	_	_	_	_
32	for	_	_	IN	_	_	_	_	_
33	protection	_	_	NN	_	_	_	_	_
34	against	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	parasite	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	high-throughput	_	_	JJ	_	_	_	_	_
5	search	_	_	NN	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	epitopes	_	_	NNS	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	this	_	_	DT	_	_	_	_	_
10	potential	_	_	NN	_	_	_	_	_
11	has	_	_	VBZ	_	_	_	_	_
12	become	_	_	VBN	_	_	_	_	_
13	one	_	_	CD	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	greatest	_	_	JJS	_	_	_	_	_
17	current	_	_	JJ	_	_	_	_	_
18	challenges	_	_	NNS	_	_	_	_	_
19	for	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	rational	_	_	JJ	_	_	_	_	_
22	design	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	vaccines	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	reverse	_	_	JJ	_	_	_	_	_
4	vaccinology	_	_	NN	_	_	_	_	_
5	started	_	_	VBD	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	be	_	_	VB	_	_	_	_	_
8	used	_	_	VBN	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	this	_	_	DT	_	_	_	_	_
11	purpose	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	one	_	_	CD	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	strategies	_	_	NNS	_	_	_	_	_
18	used	_	_	VBN	_	_	_	_	_
19	is	_	_	VBZ	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	search	_	_	NN	_	_	_	_	_
22	for	_	_	IN	_	_	_	_	_
23	immunogenic	_	_	JJ	_	_	_	_	_
24	epitopes	_	_	NNS	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	whole	_	_	JJ	_	_	_	_	_
27	Leishmania	_	_	NNP	_	_	_	_	_
28	proteomes	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Epitope	_	_	NN	_	_	_	_	_
2	mapping	_	_	NN	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	proteomes	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	parasites	_	_	NNS	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	much	_	_	RB	_	_	_	_	_
9	more	_	_	RBR	_	_	_	_	_
10	complex	_	_	JJ	_	_	_	_	_
11	than	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	mapping	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	epitopes	_	_	NNS	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	proteins	_	_	NNS	_	_	_	_	_
18	already	_	_	RB	_	_	_	_	_
19	described	_	_	VBN	_	_	_	_	_
20	as	_	_	IN	_	_	_	_	_
21	immunogenic	_	_	JJ	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	way	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	use	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	integrative	_	_	JJ	_	_	_	_	_
10	approach	_	_	NN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	immunoinformatics	_	_	NNS	_	_	_	_	_
13	proposed	_	_	VBN	_	_	_	_	_
14	by	_	_	IN	_	_	_	_	_
15	Brito	_	_	NNP	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	Guimaraes	_	_	NNP	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	Velloso	_	_	NNP	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	Correa-Oliveira	_	_	NNP	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	Ruiz	_	_	NNP	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	Reis	_	_	NNP	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	Resende	_	_	NNP	_	_	_	_	_
28	was	_	_	VBD	_	_	_	_	_
29	important	_	_	JJ	_	_	_	_	_
30	to	_	_	TO	_	_	_	_	_
31	achieve	_	_	VB	_	_	_	_	_
32	potential	_	_	JJ	_	_	_	_	_
33	epitopes	_	_	NNS	_	_	_	_	_
34	in	_	_	IN	_	_	_	_	_
35	this	_	_	DT	_	_	_	_	_
36	study	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	After	_	_	IN	_	_	_	_	_
2	employing	_	_	VBG	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	immunoinformatics	_	_	NN	_	_	_	_	_
5	methodologies	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	we	_	_	PRP	_	_	_	_	_
8	identified	_	_	VBD	_	_	_	_	_
9	MHC	_	_	NNP	_	_	_	_	_
10	class	_	_	NN	_	_	_	_	_
11	I	_	_	PRP	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	class	_	_	NN	_	_	_	_	_
14	II	_	_	NNP	_	_	_	_	_
15	ligand	_	_	NN	_	_	_	_	_
16	epitopes	_	_	NNS	_	_	_	_	_
17	comprising	_	_	VBG	_	_	_	_	_
18	mouse	_	_	NN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	human	_	_	JJ	_	_	_	_	_
21	alleles	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	due	_	_	JJ	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	absence	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	predictors	_	_	NNS	_	_	_	_	_
29	comprising	_	_	VBG	_	_	_	_	_
30	dog	_	_	NN	_	_	_	_	_
31	alleles	_	_	NNS	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	based	_	_	VBN	_	_	_	_	_
4	on	_	_	IN	_	_	_	_	_
5	some	_	_	DT	_	_	_	_	_
6	studies	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	we	_	_	PRP	_	_	_	_	_
9	can	_	_	MD	_	_	_	_	_
10	verify	_	_	VB	_	_	_	_	_
11	that	_	_	IN	_	_	_	_	_
12	there	_	_	EX	_	_	_	_	_
13	are	_	_	VBP	_	_	_	_	_
14	high	_	_	JJ	_	_	_	_	_
15	levels	_	_	NNS	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	identity	_	_	NN	_	_	_	_	_
18	between	_	_	IN	_	_	_	_	_
19	MHC	_	_	NNP	_	_	_	_	_
20	alleles	_	_	NNS	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	dogs	_	_	NNS	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	those	_	_	DT	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	humans	_	_	NNS	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	mice	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	example	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	some	_	_	DT	_	_	_	_	_
5	loci	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	MHC	_	_	NNP	_	_	_	_	_
9	region	_	_	NN	_	_	_	_	_
10	II	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	dogs	_	_	NNS	_	_	_	_	_
13	have	_	_	VBP	_	_	_	_	_
14	an	_	_	DT	_	_	_	_	_
15	identity	_	_	NN	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	those	_	_	DT	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	humans	_	_	NNS	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	mice	_	_	NNS	_	_	_	_	_
22	around	_	_	IN	_	_	_	_	_
23	85	_	_	CD	_	_	_	_	_
24	%	_	_	NN	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	79	_	_	CD	_	_	_	_	_
27	%	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	respectively	_	_	RB	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Regarding	_	_	VBG	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	vivo	_	_	NN	_	_	_	_	_
5	screening	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	immunoinformatics-selected	_	_	JJ	_	_	_	_	_
9	peptides	_	_	NNS	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	canine	_	_	NN	_	_	_	_	_
13	model	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	we	_	_	PRP	_	_	_	_	_
16	selected	_	_	VBD	_	_	_	_	_
17	asymptomatic	_	_	JJ	_	_	_	_	_
18	dogs	_	_	NNS	_	_	_	_	_
19	naturally	_	_	RB	_	_	_	_	_
20	infected	_	_	VBN	_	_	_	_	_
21	by	_	_	IN	_	_	_	_	_
22	L.	_	_	NNP	_	_	_	_	_
23	infantum	_	_	NNP	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	natural	_	_	JJ	_	_	_	_	_
26	reservoir	_	_	NN	_	_	_	_	_
27	)	_	_	-RRB-	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Several	_	_	JJ	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	shown	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	dogs	_	_	NNS	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	humans	_	_	NNS	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	asymptomatic	_	_	JJ	_	_	_	_	_
11	clinical	_	_	JJ	_	_	_	_	_
12	forms	_	_	NNS	_	_	_	_	_
13	have	_	_	VBP	_	_	_	_	_
14	better	_	_	JJR	_	_	_	_	_
15	reactivity	_	_	NN	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	intra-dermal	_	_	JJ	_	_	_	_	_
18	reaction	_	_	NN	_	_	_	_	_
19	than	_	_	IN	_	_	_	_	_
20	symptomatic	_	_	JJ	_	_	_	_	_
21	individuals	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Similarly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	Reis	_	_	NNP	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	et	_	_	FW	_	_	_	_	_
6	al.	_	_	FW	_	_	_	_	_
7	have	_	_	VBP	_	_	_	_	_
8	already	_	_	RB	_	_	_	_	_
9	shown	_	_	VBN	_	_	_	_	_
10	that	_	_	IN	_	_	_	_	_
11	asymptomatic	_	_	JJ	_	_	_	_	_
12	dogs	_	_	NNS	_	_	_	_	_
13	have	_	_	VBP	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	profile	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	circulating	_	_	VBG	_	_	_	_	_
18	lymphocytes	_	_	NNS	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	peripheral	_	_	JJ	_	_	_	_	_
22	blood	_	_	NN	_	_	_	_	_
23	capable	_	_	JJ	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	conferring	_	_	VBG	_	_	_	_	_
26	a	_	_	DT	_	_	_	_	_
27	degree	_	_	NN	_	_	_	_	_
28	of	_	_	IN	_	_	_	_	_
29	resistance	_	_	NN	_	_	_	_	_
30	to	_	_	TO	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	disease	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	When	_	_	WRB	_	_	_	_	_
2	we	_	_	PRP	_	_	_	_	_
3	performed	_	_	VBD	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	vitro	_	_	NN	_	_	_	_	_
7	screening	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	purpose	_	_	NN	_	_	_	_	_
11	was	_	_	VBD	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	identify	_	_	VB	_	_	_	_	_
14	potential	_	_	JJ	_	_	_	_	_
15	epitopes	_	_	NNS	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	huge	_	_	JJ	_	_	_	_	_
19	number	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	peptides	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	we	_	_	PRP	_	_	_	_	_
5	focused	_	_	VBD	_	_	_	_	_
6	on	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	main	_	_	JJ	_	_	_	_	_
9	biomarkers	_	_	NNS	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	protection	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	namely	_	_	RB	_	_	_	_	_
14	:	_	_	:	_	_	_	_	_
15	lymphocyte	_	_	NN	_	_	_	_	_
16	proliferation	_	_	NN	_	_	_	_	_
17	after	_	_	IN	_	_	_	_	_
18	stimulation	_	_	NN	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	L.	_	_	NNP	_	_	_	_	_
21	infantum	_	_	NN	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	IFN-Î³	_	_	NN	_	_	_	_	_
24	production	_	_	NN	_	_	_	_	_
25	by	_	_	IN	_	_	_	_	_
26	subpopulations	_	_	NNS	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	T-lymphocytes	_	_	NN	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	CD4+	_	_	NNP	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	CD8+	_	_	NNP	_	_	_	_	_
33	)	_	_	-RRB-	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Currently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	some	_	_	DT	_	_	_	_	_
4	markers	_	_	NNS	_	_	_	_	_
5	related	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	protection	_	_	NN	_	_	_	_	_
8	have	_	_	VBP	_	_	_	_	_
9	been	_	_	VBN	_	_	_	_	_
10	studied	_	_	VBN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	such	_	_	JJ	_	_	_	_	_
13	as	_	_	IN	_	_	_	_	_
14	proinflammatory	_	_	JJ	_	_	_	_	_
15	cytokines	_	_	NNS	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	production	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	immunoglobulins	_	_	NNS	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	IgG1	_	_	NNP	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	IgG2	_	_	NN	_	_	_	_	_
24	subtypes	_	_	NNS	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	responsive	_	_	JJ	_	_	_	_	_
28	CD4+	_	_	NNP	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	CD8+	_	_	NNP	_	_	_	_	_
31	T-cells	_	_	NNPS	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	biomarkers	_	_	NNS	_	_	_	_	_
3	that	_	_	WDT	_	_	_	_	_
4	we	_	_	PRP	_	_	_	_	_
5	chose	_	_	VBD	_	_	_	_	_
6	are	_	_	VBP	_	_	_	_	_
7	essential	_	_	JJ	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	determine	_	_	VB	_	_	_	_	_
10	resistance	_	_	NN	_	_	_	_	_
11	or	_	_	CC	_	_	_	_	_
12	susceptibility	_	_	NN	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	visceral	_	_	JJ	_	_	_	_	_
15	leishmaniasis	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	they	_	_	PRP	_	_	_	_	_
18	are	_	_	VBP	_	_	_	_	_
19	widely	_	_	RB	_	_	_	_	_
20	demonstrated	_	_	VBN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	literature	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	data	_	_	NNS	_	_	_	_	_
3	support	_	_	VBP	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	some	_	_	DT	_	_	_	_	_
6	peptides	_	_	NNS	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	able	_	_	JJ	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	induce	_	_	VB	_	_	_	_	_
11	lymphoproliferation	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	production	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	IFN-Î³	_	_	NNP	_	_	_	_	_
17	by	_	_	IN	_	_	_	_	_
18	T-cells	_	_	NNS	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	vitro	_	_	FW	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	regard	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	many	_	_	JJ	_	_	_	_	_
7	studies	_	_	NNS	_	_	_	_	_
8	reporting	_	_	VBG	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	use	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	murine	_	_	NN	_	_	_	_	_
13	model	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	PBMC	_	_	NNP	_	_	_	_	_
16	from	_	_	IN	_	_	_	_	_
17	patients	_	_	NNS	_	_	_	_	_
18	with	_	_	IN	_	_	_	_	_
19	leishmaniasis	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	main	_	_	JJ	_	_	_	_	_
23	biomarker	_	_	NN	_	_	_	_	_
24	analyzed	_	_	VBD	_	_	_	_	_
25	was	_	_	VBD	_	_	_	_	_
26	IFN-Î³	_	_	NNP	_	_	_	_	_
27	produced	_	_	VBN	_	_	_	_	_
28	after	_	_	IN	_	_	_	_	_
29	stimuli	_	_	NNS	_	_	_	_	_
30	with	_	_	IN	_	_	_	_	_
31	different	_	_	JJ	_	_	_	_	_
32	peptides	_	_	NNS	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	After	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	vitro	_	_	NN	_	_	_	_	_
5	screening	_	_	NN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	reverse	_	_	JJ	_	_	_	_	_
9	antigen	_	_	NN	_	_	_	_	_
10	screening	_	_	NN	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	RAS	_	_	NNP	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	was	_	_	VBD	_	_	_	_	_
15	used	_	_	VBN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	robust	_	_	JJ	_	_	_	_	_
19	methodology	_	_	NN	_	_	_	_	_
20	that	_	_	WDT	_	_	_	_	_
21	allows	_	_	VBZ	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	selection	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	promising	_	_	JJ	_	_	_	_	_
26	targets	_	_	NNS	_	_	_	_	_
27	for	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	development	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	vaccines	_	_	NNS	_	_	_	_	_
32	intended	_	_	VBN	_	_	_	_	_
33	to	_	_	TO	_	_	_	_	_
34	trigger	_	_	VB	_	_	_	_	_
35	a	_	_	DT	_	_	_	_	_
36	strong	_	_	JJ	_	_	_	_	_
37	cellular	_	_	JJ	_	_	_	_	_
38	response	_	_	NN	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	findings	_	_	NNS	_	_	_	_	_
3	demonstrate	_	_	VBP	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	immunoinformatic	_	_	JJ	_	_	_	_	_
7	approach	_	_	NN	_	_	_	_	_
8	increases	_	_	VBZ	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	chance	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	finding	_	_	VBG	_	_	_	_	_
13	peptides	_	_	NNS	_	_	_	_	_
14	molecules	_	_	NNS	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	epitopes	_	_	NNS	_	_	_	_	_
17	)	_	_	-RRB-	_	_	_	_	_
18	which	_	_	WDT	_	_	_	_	_
19	can	_	_	MD	_	_	_	_	_
20	trigger	_	_	VB	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	cellular	_	_	JJ	_	_	_	_	_
23	response	_	_	NN	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	naturally	_	_	RB	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	asymptomatic	_	_	JJ	_	_	_	_	_
29	infected	_	_	VBN	_	_	_	_	_
30	model	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	fact	_	_	NN	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	an	_	_	DT	_	_	_	_	_
5	antigen	_	_	NN	_	_	_	_	_
6	generates	_	_	VBZ	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	cellular	_	_	JJ	_	_	_	_	_
9	response	_	_	NN	_	_	_	_	_
10	classified	_	_	VBN	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	type	_	_	NN	_	_	_	_	_
13	IV	_	_	NN	_	_	_	_	_
14	or	_	_	CC	_	_	_	_	_
15	late	_	_	JJ	_	_	_	_	_
16	hypersensitivity	_	_	NN	_	_	_	_	_
17	implies	_	_	VBZ	_	_	_	_	_
18	that	_	_	IN	_	_	_	_	_
19	this	_	_	DT	_	_	_	_	_
20	antigen	_	_	NN	_	_	_	_	_
21	may	_	_	MD	_	_	_	_	_
22	be	_	_	VB	_	_	_	_	_
23	able	_	_	JJ	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	generate	_	_	VB	_	_	_	_	_
26	immune	_	_	JJ	_	_	_	_	_
27	memory	_	_	NN	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	trigger	_	_	VB	_	_	_	_	_
30	a	_	_	DT	_	_	_	_	_
31	response	_	_	NN	_	_	_	_	_
32	characterized	_	_	VBN	_	_	_	_	_
33	by	_	_	IN	_	_	_	_	_
34	important	_	_	JJ	_	_	_	_	_
35	cytokines	_	_	NNS	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	such	_	_	JJ	_	_	_	_	_
38	as	_	_	IN	_	_	_	_	_
39	IFN-Î³	_	_	NNP	_	_	_	_	_
40	and	_	_	CC	_	_	_	_	_
41	TNF-Î±	_	_	NNP	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	When	_	_	WRB	_	_	_	_	_
2	we	_	_	PRP	_	_	_	_	_
3	analyzed	_	_	VBD	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	epitope	_	_	NN	_	_	_	_	_
6	conservancy	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	these	_	_	DT	_	_	_	_	_
9	peptides	_	_	NNS	_	_	_	_	_
10	among	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	proteome	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	other	_	_	JJ	_	_	_	_	_
15	Leishmania	_	_	NNP	_	_	_	_	_
16	species	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	it	_	_	PRP	_	_	_	_	_
19	was	_	_	VBD	_	_	_	_	_
20	observed	_	_	VBN	_	_	_	_	_
21	that	_	_	IN	_	_	_	_	_
22	peptide	_	_	NN	_	_	_	_	_
23	PEP17	_	_	NNP	_	_	_	_	_
24	demonstrated	_	_	VBD	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	be	_	_	VB	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	most	_	_	RBS	_	_	_	_	_
29	conserved	_	_	VBN	_	_	_	_	_
30	epitope	_	_	NN	_	_	_	_	_
31	among	_	_	IN	_	_	_	_	_
32	various	_	_	JJ	_	_	_	_	_
33	viscerotropic	_	_	JJ	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	dermatotropic	_	_	JJ	_	_	_	_	_
36	Leishmania	_	_	NN	_	_	_	_	_
37	species	_	_	NNS	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Immunogenic	_	_	JJ	_	_	_	_	_
2	peptides	_	_	NNS	_	_	_	_	_
3	that	_	_	WDT	_	_	_	_	_
4	show	_	_	VBP	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	high	_	_	JJ	_	_	_	_	_
7	degree	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	conservancy	_	_	NN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	other	_	_	JJ	_	_	_	_	_
12	parasites	_	_	NNS	_	_	_	_	_
13	may	_	_	MD	_	_	_	_	_
14	be	_	_	VB	_	_	_	_	_
15	related	_	_	VBN	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	better	_	_	JJR	_	_	_	_	_
19	protection	_	_	NN	_	_	_	_	_
20	when	_	_	WRB	_	_	_	_	_
21	compared	_	_	VBN	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	those	_	_	DT	_	_	_	_	_
24	not	_	_	RB	_	_	_	_	_
25	conserved	_	_	VBN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	way	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	peptides	_	_	NNS	_	_	_	_	_
6	17	_	_	CD	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	30	_	_	CD	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	33	_	_	CD	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	34	_	_	CD	_	_	_	_	_
14	may	_	_	MD	_	_	_	_	_
15	be	_	_	VB	_	_	_	_	_
16	considered	_	_	VBN	_	_	_	_	_
17	promising	_	_	JJ	_	_	_	_	_
18	epitopes	_	_	NNS	_	_	_	_	_
19	for	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	design	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	vaccines	_	_	NNS	_	_	_	_	_
24	against	_	_	IN	_	_	_	_	_
25	VL	_	_	NNP	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_

